Overview

• XH06 binds selectively to glypican-3, a cell surface receptor overexpressed in most hepatocellular carcinoma tumors.
• In Wuhan Union Hospital’s pilot study, the tracer achieved 90.63% sensitivity and 100% specificity against surgical pathology.
• The agent clearly delineated lesions under one centimeter, a level of resolution that conventional CT and MRI often miss.
• Pharmacokinetic data showed rapid blood clearance and renal excretion with minimal off-target uptake.
• If confirmed in larger trials, this molecular imaging approach could enable earlier staging and intervention for a cancer with an 18% five-year survival rate.